Cardiovascular

Multidisciplinary care enhances kidney health and cardiovascular outcomes, but more research into models is needed, said Roy Mathew, MD.

New treatments, care gaps, and cardiac monitoring were major focuses in cardiovascular news this year.

From oncology to cardiology, Institute for Value-Based Medicine® conversations highlighted the ways value-based care is reshaping access, equity, and outcomes.

The meeting included new evidence and expert insights on hormone therapy, AI, and the expanding role of GLP-1 therapies in cardiovascular care.

Lerodalcibep-liga subcutaneous injection is now approved for adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia.

Semaglutide, sotatercept, and bentracimab trials were attendees’ main focus at the American College of Cardiology 2025 Annual Scientific Session.

Patients aged 30 to 40 years with type 1 diabetes had the highest risk of sudden cardiac death, according to 2010 data from Denmark.

Phase 3 OCEANIC-STROKE data show how asundexian offers a potential new secondary stroke prevention option.

Svetlana Barbarash, MD, outlines the lack of cardiologists and transplant services in Las Vegas and the policy changes needed to close gender gaps in care.

Svetlana Barbarash, MD, explains how better education, digital monitoring tools, and coordinated care can improve arrhythmia detection and outcomes.

Researchers urged caution in interpreting DECAF Trial results that suggest daily coffee intake is linked to a lower risk of atrial fibrillation recurrence.

Online health discussions can influence patient behaviors, but misinformation spreads easily. Khush Kharidia, MD, UT Southwestern, explains how creator credibility impacts cholesterol-related health information.

SGLT2 inhibitors may worsen heart failure outcomes from chemotherapy, highlighting the need for further long-term studies on cardiotoxicity, explains Rakendu Rajendran, MBBS.

Lindsey Valenzuela, PharmD, explains how value-based models empower a single pharmacist to manage multiple layers of these disease states.

Lindsey Valenzuela, PharmD, explains how pharmacists can prevent drug interactions and improve coordination for women with arrhythmia and chronic disease.

Lindsey Valenzuela, PharmD, explains how cost, coverage gaps, and tech literacy hinder women’s access to early arrhythmia detection tools.

Lindsey Valenzuela, PharmD, explains how atypical symptoms, research gaps, and care inequities delay arrhythmia detection in women.

Primary aldosteronism is often overlooked in hypertension. Educating providers and utilizing tools can enhance screening and treatment effectiveness, emphasizes Vivek Bhalla, MD, Stanford.

Research reveals that patients with both rheumatoid arthritis and MASH cirrhosis face significantly higher cardiovascular risks.

New findings reveal sotatercept's significant benefits for right ventricular function and tricuspid regurgitation in pulmonary arterial hypertension.

From 2017 to 2023, women were especially underrepresented in trials in arrhythmia, coronary heart disease, acute coronary syndrome, and heart failure.

The drug lowered inflammation, oxidative stress, and endothelial injury markers in women with INOCA and coronary microvascular dysfunction.

Patients’ misperceptions of statins and physicians’ limited knowledge of a hypercholesterolemia safety-net program warrant additional interventions to reduce barriers and improve care.

Renal denervation modestly lowers blood pressure, with durable long-term benefits, according to Deepak L. Bhatt, MD, MPH, MBA.

Evolocumab is now indicated for adults who don’t have a prior cardiovascular disease diagnosis.